Positron emission tomography for detection and classification of lung cancer;18F-fluorodeoxyglukose-positronenemissions-tomographie zur diagnostik des bronchialkarzinoms

Acta Medica Austriaca

Volumn 29, Issue 5, 2002, Pages 171-175

  Bares, R ^a   Eschmann, S M ^b   Friedel, G ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NONE

Author keywords

Hypoxia; Lung cancer; Position emission tomography; Proliferation; Solitary pulmonary nodule; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CELL PROLIFERATION; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; HYPOXIA; IN VIVO STUDY; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; METASTASIS; NON INVASIVE MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENT CANCER; TREATMENT OUTCOME; CANCER STAGING; CELL DIVISION; CLASSIFICATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LUNG TUMOR; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036882295     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-2571.2002.02043.x     Document Type: Article

References (39)

1. Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R, Ginsberg RJ, Rusch VW, Larsson SM: An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002;73: 259-266.
2. Berlangieri SU, Scott AM, Knight SR, Fitt GJ, Hennessy OF, Tochon-Danguy HJ, Clarke CP, McKay WJ: F-18 flourodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Card Thorac Surg 1999;16: 25-30.
3. Bury T, Dowlati A, Paulus P, Corhay JL, Benoit T, Kayembe JM, Limet R, Rigo P, Radermecker M: Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9: 410-414.
4. 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Resp J 1997;10: 2529-2534.
5. Bury T, Corhay JL, Duysinx B, Daenen F, Ghaye B, Barthelemy N, Rigo P, Bartsch P: Value of FDG PET in detecting residual or recurrent non-small cell lung cancer. Eur Resp J 1999;14: 1376-1380.
6. Chin R, Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt S, Hudspeth AS, Haponik EF: Mediastinal Staging of Non-Small Cell Lung Cancer with Positron Emission Tomography. Am J Respir Crit Care Med 1995;152: 2090-2096.
7. Coleman R: Multicenter prospective study of FDG-PET in the evaluation of indeterminate solitary pulmonary nodules. J Nucl Med 1995;36:94P.
8. Dewan NA, Shehan CJ, Reeb SD, Gobar LS, Scott WJ, Ryschon K: Likelihood of Malignancy in a solitary pulmonary nodule-Comparison of Bayesian analysis and results of FDG-PET scan. Chest 1997;112: 417-422.
9. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, Schicha H: Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000;27: 1441-1456.
10. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, Schicha H: Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000;27: 1598-1609.
11. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, Yorke ED: Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000;27: 861-866.
12. Eschmann SM, Friedel G, Dohmen BM, Budach W, Paulsen F, Harer-Mouline C, Bares R: FDG-PET for staging of advanced non-small lung cancer prior to neoadjuvant radio-chemotherapy. J Nucl Med 2001;42(Suppl 5):150P.
13. Friedel G, Hruska D, Budach W, Wolf M, Kyriss T, Hürtgen M, Eulenbruch HP, Dierkesmann R, Toomes H: Neoadjuvant chemoradiotherapy of stage III non-small cell lung cancer. Lung Cancer 2000;30: 175-185.
14. Fujiwara T, Matsuzawa T, Kubota K, Abe Y, Itoh M, Fukuda H, Hatazawa J, Yoshioka S, Yamaguchi K, Ito K, Watanuki S, Takahashi T, Ishiwata K, Iwata R, Ido T: Relatioship between histologic type of primary lung cancer and carbon-11-L-methionine uptake with positron emission tomography. J Nucl Med 1989;30: 33-37.
15. Gould MK, Lillington GA: Strategy and cost in investigating solitary pulmonary nodules. Thorax 1998;53(Suppl 2): 32-37.
16. 18F]FDG positron emission tomography. Thorax 1997;52: 438-441.
17. Gupta NC, Maloof J, Gunel E: Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996;37: 943-948.
18. Gupta NC, Graeber GM, Rogers JS, Bishop HA: Comparative Efficacy of Positron Emission Tomography with FDG and Computed Tomographic Scanning in Preoperative Staging of Non-Small Cell Lung Cancer. Ann Surg 1999;229: 286-291.
19. Hellwig D, Ukena D, Sybrecht GW, Kirsch CM: Hohe Aussagekraft der FDG-PET Untersuchung beim Bronchiolo-Alveoloarzell-Karzinom. Nucl Med 2001;40:A24.
20. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, Seki H, Taki S, Tonami H, Yamamoto I: FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43: 39-45.
21. Inoue T, Kim EE, Komaki R, Wong FCL, Bassa P, Wong WH, Yang DJ, Endo K, Podoloff DA: Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36: 788-793.
22. Kerstine KH, Kelley A, McLaughlin RN, Menda Y, Rossi NP, Kahn DJ, Bushnell DL, Graham MM, Brown CK, Madsen MT: Can FDG-PET reduce the need for mediastinoscopy in potentially resectable non-small cell lung cancer. Ann Thorac Surg 2002;73: 394-402.
23. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, Iwata R, Ido T: Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31: 1927-1933.
24. Lee J, Aronchick JM, Alavi A: Accuracy of F-18 Fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities. Chest 2001;120: 1791-1797.
25. Lewis PJ, Salama A: Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994;35: 1647-1649.
26. Lowe VJ, Delong DM, Duhaylongsod FG, Patz EF, Wolfe WG, Coleman RE: FDG-PET evaluation of focal pulmonary abnormalities. J Nucl Med 1995;36:94P.
27. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, Karis J, Hubner K, Delbeke D, Heiberg EV, Patz EF, Coleman RE: Prospective investigation of positron emission tomography in lung nodules. J Clin Invest 1998;16: 1075-1084.
28. Patz EF, Lowe VJ, Hoffmann JM, Paine SS, Burrowes P, Coleman RE, Goodman PC: Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188: 87-90.
29. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC: Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-(F-18)-2-deoxy-D-glucose. Radiology 1994;191: 379-382.
30. Pietermamn R, Willemsen A, Appel M, Pruim J, Koeter G, Vaalburg W, Groen H: Visualization and assessment of protein synthesis rate of lung cancer using carbon-11 tyrosine and positron emission tomography. Eur J Nucl Med 2002;29: 243-247.
31. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA: Quantifying regional hypoxia in human tumors with positron emission tomography of 18-F fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36: 417-428.
32. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ: FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35: 179-187.
33. Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T, Murayama S, Ishida T, Sugio K, Masuda K: The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996;23: 741-747.
34. Schumacher T, Brink I, Mix M, einhardt M, Herget G, Digel W, Henke M, Moser E, Nitzsche E: FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001;28: 483-488.
35. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich BSJE, Muzik O, Manger TJ: Imaging proliferation in vivo with F-18 FLT and positron emission tomography. Nature Med 1998;4: 1334-1336.
36. Steinert HC, Hauser M., Allemann F, Engel H, Bertold T, von Schulthess GK, Weder W: Non-Small Cell Lung Cancer: Nodal Staging with FDG PET versus CT with Correlative Lymph Node Mapping and Sampling. Radiology 1997;202: 441-446.
37. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, Myers RW, Lutrin CL: Staging Non-Small Cell Lung Cancer by Whole-Body Positron Emission Tomographic Imaging. Ann Thorac Surg 1995;60: 1573-1582.
38. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, Deneffe GJ, Nackaerts KL, Verschakelen JA, Lerut TE, Mortelmans LA, Demedts MG: Lymph Node Staging in Non-Small Cell Lung Cancer with FDG PET Scan: A Prospective Study on 690 Lymph Node Stations From 68 Patients. J Clin Onc 1998;16: 2142-2149.
39. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB: Staging of Mediastinal Non-Small Cell Lung Cancer with FDG PET, CT, and Fusion Images: Preliminary Prospective Evaluation. Radiology 1994;191: 371-377.